Guizhi Fuling pill attenuates liver fibrosis <i>in vitro</i> and <i>in vivo</i> via inhibiting TGF-β1/Smad2/3 and activating IFN-γ/Smad7 signaling pathways-Reference-Cited by-同舟云学术

Guizhi Fuling pill attenuates liver fibrosis in vitro and in vivo via inhibiting TGF-β1/Smad2/3 and activating IFN-γ/Smad7 signaling pathways

Published:2022-04-01 Issue:4 Volume:13 Page:9357-9368
ISSN:2165-5979
Container-title:Bioengineered
language:en
Short-container-title:Bioengineered

Author:

Liu Zhongliang¹,Xu Baogui²,Ding Yaping³,Ding Xianjun⁴⁵,Yang Zuisu²

Affiliation:

1. Department of Oncology, Zhoushan Hospital of Traditional Chinese Medicine (Affiliated to Zhejiang University of Traditional Chinese Medicine), Zhoushan, P.R. China

2. School of Food and Pharmacy, Zhejiang Ocean University, Zhoushan, China

3. Department of Nutrition, Zhoushan Hospital of Traditional Chinese Medicine (Affiliated to Zhejiang University of Traditional Chinese Medicine), Zhoushan, P.R. China

4. Department of Infectious Diseases, Zhoushan Hospital of Traditional Chinese Medicine (Affiliated to Zhejiang University of Traditional Chinese Medicine), Zhoushan, P.R. China

5. Department of Infectious Diseases, Zhoushan Hospital, P.R. China

Funder

Zhejiang Provincial Key Research Project of Traditional Chinese Medicine Science and Technology Plan, China

Publisher

Informa UK Limited

Subject

Applied Microbiology and Biotechnology,General Medicine,Bioengineering,Biotechnology

Link

https://www.tandfonline.com/doi/pdf/10.1080/21655979.2022.2054224

Reference50 articles.

1. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues

2. Liver fibrosis